Market Spotlight: Biliary Tract Cancer
|出版日期||內容資訊||英文 45 Pages
|市場焦點:膽道癌症 Market Spotlight: Biliary Tract Cancer|
|出版日期: 2020年08月07日||內容資訊: 英文 45 Pages||
This Market Spotlight report covers the Biliary Tract Cancer market, comprising key pipeline drugs, recent events and analyst opinion, clinical trials, upcoming events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.
Datamonitor Healthcare estimates that in 2019, there were approximately 405,800 incident cases of biliary tract cancer (BTC) worldwide, and forecasts that number to increase to 433,300 incident cases by 2028.
The only approved drug in the BTC space is Pemazyre, which targets fibroblast growth factor receptor. It is administered via the oral route.
The majority of industry-sponsored drugs in active clinical development for BTC are in Phase II. Therapies in development for BTC focus on a wide variety of targets, with the majority being administered via the oral or intravenous routes.
High-impact upcoming events for drugs in the BTC space comprise topline Phase II trial results for M7824, topline Phase IIa trial results for Xermelo, topline Phase IIb/III trial results for sulfatinib, topline Phase III trial results for Imfinzi and fimaCHEM, and an expected CHMP opinion for Pemazyre.
The overall likelihood of approval of a Phase I solid tumors asset is 5.8%, and the average probability a drug advances from Phase III is 43.3%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.4 years in the overall oncology space.
The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for biliary tract neoplasms have been in the early and mid-phases of development, with 90% of trials in Phase I-II, and only 10% in Phase III-IV.
The US has a substantial lead in the number of biliary tract neoplasms clinical trials globally. The UK leads the major European markets, while South Korea has the top spot in Asia.
Eli Lilly has the highest number of completed clinical trials for biliary tract neoplasms, with five trials.
AstraZeneca leads industry sponsors with the highest overall number of clinical trials for biliary tract neoplasms.